Could a single nasal spray stop asthma Flare-Ups from colds?

NCT ID NCT07059767

Recruiting now Disease control Sponsor: Ethris GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of a nasal spray called ETH47 can reduce asthma symptoms caused by a common cold virus (rhinovirus). Fifty adults with stable asthma will receive either the spray or a placebo and then be exposed to the virus in a controlled setting. Researchers will track lower respiratory symptoms over time to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ETH47 (a nasal spray drug)
What this could lead to: If it works, this could point toward a new way to prevent asthma flare-ups caused by colds.
What could go wrong: This is an early Phase IIa trial with only 50 people, so results may not apply to everyone. The drug is tested in a controlled lab setting, not real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA (DIAGNOSIS)

Contacts and locations

Locations

Imperial College Healthcare NHS Trust
RECRUITING

London, United Kingdom
Medicines Evaluation Unit Limited
RECRUITING

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.